Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABCL 
Abcellera Biologics Inc (ABCL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ABCL (4-star) is a STRONG-BUY. BUY since 20 days. Simulated Profits (29.24%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.33
1 Year Target Price $9.33
| 6 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 17.3% | Avg. Invested days 28 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.68B USD | Price to earnings Ratio - | 1Y Target Price 9.33 |
Price to earnings Ratio - | 1Y Target Price 9.33 | ||
Volume (30-day avg) 9 | Beta 0.69 | 52 Weeks Range 1.89 - 6.51 | Updated Date 10/15/2025 |
52 Weeks Range 1.89 - 6.51 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -290.24% |
Management Effectiveness
Return on Assets (TTM) -10.96% | Return on Equity (TTM) -15.64% |
Valuation
Trailing PE - | Forward PE 27.47 | Enterprise Value 1376022819 | Price to Sales(TTM) 51.08 |
Enterprise Value 1376022819 | Price to Sales(TTM) 51.08 | ||
Enterprise Value to Revenue 41.85 | Enterprise Value to EBITDA 5.3 | Shares Outstanding 298832913 | Shares Floating 202749166 |
Shares Outstanding 298832913 | Shares Floating 202749166 | ||
Percent Insiders 22.94 | Percent Institutions 38.7 |
Upturn AI SWOT
Abcellera Biologics Inc
Company Overview
History and Background
AbCellera Biologics Inc. was founded in 2012. It is a Canadian biotechnology company focused on antibody discovery and development. AbCellera's technology platform integrates data science, artificial intelligence, machine learning, and microfluidics to screen and analyze single cells to find and develop therapeutic antibodies.
Core Business Areas
- Antibody Discovery: AbCellera's primary business is discovering and developing therapeutic antibodies for pharmaceutical and biotechnology companies. They use their proprietary platform to identify antibodies with desired characteristics.
- Partnerships & Licensing: AbCellera partners with other companies to discover and develop antibodies. They receive upfront payments, research funding, and milestone payments.
Leadership and Structure
Dr. Carl Hansen is the CEO of AbCellera. The company has a typical corporate structure with various departments for research, development, operations, and finance.
Top Products and Market Share
Key Offerings
- Antibody Discovery Platform: AbCellera's integrated platform enables rapid and comprehensive antibody discovery. Revenue is derived through partnerships with pharmaceutical companies. Competitors include companies with in-house antibody discovery capabilities (e.g., Regeneron, Genmab).
Market Dynamics
Industry Overview
The antibody discovery market is large and growing, driven by the increasing demand for antibody-based therapies to treat various diseases, including cancer and infectious diseases.
Positioning
AbCellera is positioned as a technology leader in antibody discovery due to its integrated platform and AI-driven approach. They aim to provide faster and more efficient antibody discovery compared to traditional methods.
Total Addressable Market (TAM)
The total addressable market for antibody discovery is estimated to be in the billions of dollars annually. AbCellera is positioned to capture a significant portion of this market through its partnerships and technology.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Strong partnerships with pharmaceutical companies
- Expertise in antibody discovery
- Data-driven approach
Weaknesses
- Reliance on partnerships for revenue
- High research and development costs
- Competition from established players
- Dependence on key personnel
Opportunities
- Expanding partnerships with more pharmaceutical companies
- Developing new antibody-based therapies
- Leveraging AI and machine learning to improve antibody discovery
- Acquiring complementary technologies or companies
Threats
- Competition from other antibody discovery companies
- Failure to discover and develop successful antibodies
- Changes in the regulatory environment
- Economic downturn
Competitors and Market Share
Key Competitors
- LLY
- REGN
- GSK
- CMPS
Competitive Landscape
AbCellera's advantages include its integrated platform and AI-driven approach. Disadvantages include its reliance on partnerships and competition from established players.
Growth Trajectory and Initiatives
Historical Growth: AbCellera's historical growth has been driven by increasing partnerships and revenue from antibody discovery programs.
Future Projections: Future growth is expected to come from expanding partnerships and developing new antibody-based therapies.
Recent Initiatives: Recent initiatives include expanding the company's technology platform, and focusing on high value therapeutic targets.
Summary
AbCellera is a biotechnology company specializing in AI-powered antibody discovery with a strong technology platform. They rely heavily on partnerships, which brings both opportunities and challenges. Their reliance on partnerships presents a risk if collaboration agreements don't materialize as expected. AbCellera's innovative approach to antibody discovery has the potential to disrupt the biopharmaceutical industry and its future will depend on successful execution of its partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market data and financial information are subject to change. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abcellera Biologics Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2020-12-11 | CEO, President & Chairperson Dr. Carl L.G. Hansen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 596 | Website https://www.abcellera.com |
Full time employees 596 | Website https://www.abcellera.com | ||
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.